Extracellular matrix differences in glioblastoma patients with different prognoses

József Virga, László Szivos, T. Hortobágyi, Mahan Kouhsari Chalsaraei, Gábor Zahuczky, László Steiner, J. Tóth, Judit Reményi-Puskár, L. Bognár, A. Klekner

Research output: Contribution to journalArticle

Abstract

Glioblastoma is the most common malignant central nervous system tumor. Patient outcome remains poor despite the development of therapy and increased understanding of the disease in the past decades. Glioma cells invade the peritumoral brain, which results in inevitable tumor recurrence. Previous studies have demonstrated that the extracellular matrix (ECM) is altered in gliomas and serves a major role in glioma invasion. The present study focuses on differences in the ECM composition of tumors in patients with poor and improved prognosis. The mRNA and protein expression of 16 invasion-associated ECM molecules was determined using reverse trascription-quantitiative polymerase chain reaction and immunohistochemistry, respectively. Clinical factors of patients with different prognoses was also analyzed. It was determined that age and postoperative Karnofsky performance score were associated with patient survival. Furthermore, Fms-related tyrosine kinase 4/vascular endothelial growth factor receptor 3 (FLT4/VEGFR3), murine double minute 2 (MDM2) and matrix metallopeptidase 2 (MMP2) mRNA levels were significantly different between the two prognostic groups. Additionally, brevican, cluster of differentiation 44, hyaluronan mediated motility receptor, integrin-αV and -β1, and MDM2 protein expression were indicated to be significantly different in immunohistochemistry slides. Using the expression profile, including the invasion spectrum of the samples, it was possible to identify the prognostic group of the sample with high efficacy, particularly in cases with poor prognosis. In conclusion, it was determined that ECM components exhibit different expression levels in tumors with different prognoses and thus the invasion spectrum can be used as a prognostic factor in glioblastoma.

Original languageEnglish
Pages (from-to)797-806
Number of pages10
JournalOncology Letters
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

    Fingerprint

Keywords

  • Expression
  • Extracellular matrix
  • Glioblastoma
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this